CR20210056A - Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa - Google Patents

Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa

Info

Publication number
CR20210056A
CR20210056A CR20210056A CR20210056A CR20210056A CR 20210056 A CR20210056 A CR 20210056A CR 20210056 A CR20210056 A CR 20210056A CR 20210056 A CR20210056 A CR 20210056A CR 20210056 A CR20210056 A CR 20210056A
Authority
CR
Costa Rica
Prior art keywords
compounds
heterocyclic compounds
new heterocyclic
monoacylglycerol lipase
lipase inhibitors
Prior art date
Application number
CR20210056A
Other languages
English (en)
Inventor
Bernd Kuhn
Dominik Heer
Hans Richter
Fionn O`Hara
Uwe Grether
Joerg Benz
Lilli Anselm
Katrin Groebke-Zbinden
Carsten Kroll
Benoit Hornsperger
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20210056A publication Critical patent/CR20210056A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

<p>La invención proporciona nuevos compuestos heterocíclicos que tienen la fórmula general (I) en donde A, L, X, m, n, R<sup>1</sup> y R<sup>2</sup> son como se describen en el presente documento, composiciones que incluyen los compuestos, procesos de fabricación de los compuestos, métodos de uso de los compuestos y métodos para determinar la actividad inhibidora de monoacilglicerol lipasa (MAGL) de los compuestos</p>
CR20210056A 2018-08-13 2019-08-12 Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa CR20210056A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18188679 2018-08-13
PCT/EP2019/071522 WO2020035425A1 (en) 2018-08-13 2019-08-12 New heterocyclic compounds as monoacylglycerol lipase inhibitors

Publications (1)

Publication Number Publication Date
CR20210056A true CR20210056A (es) 2021-03-02

Family

ID=63244466

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210056A CR20210056A (es) 2018-08-13 2019-08-12 Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa

Country Status (19)

Country Link
US (1) US20210277020A1 (es)
EP (1) EP3837264A1 (es)
JP (1) JP2021533093A (es)
KR (1) KR20210044217A (es)
CN (1) CN112469724A (es)
AR (1) AR115949A1 (es)
AU (1) AU2019322161A1 (es)
BR (1) BR112020025642A2 (es)
CA (1) CA3098272A1 (es)
CL (1) CL2021000361A1 (es)
CR (1) CR20210056A (es)
IL (1) IL280762A (es)
MA (1) MA53220A (es)
MX (1) MX2020013719A (es)
PE (1) PE20211380A1 (es)
PH (1) PH12021500015A1 (es)
SG (1) SG11202012222TA (es)
TW (1) TWI814882B (es)
WO (1) WO2020035425A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
TW201936602A (zh) 2017-11-28 2019-09-16 瑞士商赫孚孟拉羅股份公司 新雜環化合物
EP3737680A1 (en) 2018-01-08 2020-11-18 F. Hoffmann-La Roche AG Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
WO2019168847A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
KR20210049090A (ko) 2018-07-05 2021-05-04 인사이트 코포레이션 A2a/a2b 억제제로서 융합된 피라진 유도체
FI3837263T3 (fi) 2018-08-13 2024-09-03 Hoffmann La Roche Uusia heterosyklisiä yhdisteitä monoasyyliglyserolilipaasin estäjinä
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US20210094971A1 (en) * 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
WO2021048241A1 (en) * 2019-09-12 2021-03-18 F. Hoffmann-La Roche Ag Radiolabeled compounds
EP4028403B1 (en) 2019-09-12 2023-11-22 F. Hoffmann-La Roche AG 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors
WO2021058416A1 (en) * 2019-09-23 2021-04-01 F. Hoffmann-La Roche Ag Heterocyclic compounds
WO2021058445A1 (en) * 2019-09-24 2021-04-01 F. Hoffmann-La Roche Ag New heterocyclic monoacylglycerol lipase (magl) inhibitors
MX2022002831A (es) * 2019-09-24 2022-04-06 Hoffmann La Roche Compuestos heterociclicos.
IL299664A (en) 2020-09-03 2023-03-01 Hoffmann La Roche Heterocyclic compounds
WO2024031088A1 (en) 2022-08-05 2024-02-08 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579495B2 (en) 2003-12-19 2009-08-25 Momentive Performance Materials Inc. Active-releasing cyclic siloxanes
FR2915197B1 (fr) * 2007-04-18 2009-06-12 Sanofi Aventis Sa Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.
TW200942537A (en) * 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
RU2538204C2 (ru) 2009-09-10 2015-01-10 Ф.Хоффманн-Ля Рош Аг Ингибиторы jak
WO2011059118A1 (ko) 2009-11-10 2011-05-19 Kim Hyun Jeen 후각인지능력 검사 시스템
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
JP2014533747A (ja) * 2011-11-30 2014-12-15 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ３，７−二置換オクタヒドロ−２Ｈ−ピリド［４，３−ｅ］［１，３］オキサジン−２−オン抗生物質
JP6653319B2 (ja) * 2015-03-30 2020-02-26 武田薬品工業株式会社 複素環化合物
EA033680B1 (ru) 2015-05-21 2019-11-15 Glaxosmithkline Ip Dev Ltd Производные бензоимидазола в качестве ингибиторов pad4
MY194647A (en) * 2016-03-31 2022-12-09 Takeda Pharmaceuticals Co Heterocyclic compound
EP3438109B1 (en) * 2016-03-31 2021-08-25 Takeda Pharmaceutical Company Limited Heterocyclic compound

Also Published As

Publication number Publication date
CL2021000361A1 (es) 2021-07-09
PH12021500015A1 (en) 2021-09-13
EP3837264A1 (en) 2021-06-23
PE20211380A1 (es) 2021-07-27
TW202035421A (zh) 2020-10-01
MA53220A (fr) 2021-11-17
CN112469724A (zh) 2021-03-09
MX2020013719A (es) 2021-03-02
US20210277020A1 (en) 2021-09-09
IL280762A (en) 2021-04-29
JP2021533093A (ja) 2021-12-02
AU2019322161A1 (en) 2020-11-12
BR112020025642A2 (pt) 2021-03-23
CA3098272A1 (en) 2020-02-20
TWI814882B (zh) 2023-09-11
KR20210044217A (ko) 2021-04-22
WO2020035425A1 (en) 2020-02-20
SG11202012222TA (en) 2021-01-28
AR115949A1 (es) 2021-03-17

Similar Documents

Publication Publication Date Title
CR20210056A (es) Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa
MX2021001433A (es) Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
CR20200416A (es) Nuevos compuestos heterocíclicos
CR20210247A (es) Nuevos compuestos heterocíclicos
CR20220118A (es) Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl)
MX2022002311A (es) Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
MX2021000795A (es) Compuestos heterociclicos para inhibir la actividad de shp2.
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2022002554A (es) Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
MX2021002978A (es) Lactamas biciclicas y metodos de uso de las mismas.
WO2017050791A8 (en) New bicyclic compounds as dual atx/ca inhibitors
MX2021014350A (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos.
CR20220004A (es) Nuevos compuestos heterocíclicos
MX2022002831A (es) Compuestos heterociclicos.
MX2022003023A (es) Compuestos heterociclicos.
MX2023002224A (es) Compuestos heterociclicos.
CR20230496A (es) Compuestos heterocíclicos
CL2022001452A1 (es) Inhibidores de masp-2 y métodos de uso.
MX2023008634A (es) Análogos de rapamicina y usos de estos.
MX2020013518A (es) Nuevos derivados de isoxazolil eter como moduladores alostericos positivos (pam) del receptor de acido gamma-aminobutirico a alfa5 (gaba a alfa5).
EA202192237A1 (ru) Кристаллические формы ингибитора jak2
MX2021002087A (es) Derivados de heteroarilo biciclicos.
MX2022006776A (es) Composiciones farmaceuticas oftalmicas.